Compare Alcon AG (ALC) vs YieldMax AMD Option Income Strategy ETF (AMDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs YieldMax AMD Option Income Strategy ETF — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while YieldMax AMD Option Income Strategy ETF trades at $52.7. The key difference: Alcon AG pays a 0.54% dividend while YieldMax AMD Option Income Strategy ETF pays none, and YieldMax AMD Option Income Strategy ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | AMDY | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $92.22 | $59.52 |
52-Week Low | $62.02 | $29.80 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
AMDY trades at $56.10, up 5.35% in the last 24 hours, with technical indicators showing a bullish trend. The stock exhibits strong weekly dividend distributions, but key valuation and profitability ratios are unavailable. Recent news highlights high-yield potential alongside concerns over net asset value erosion due to its option income strategy.
The outlook for AMDY is mixed; high dividend yields attract income investors, but structural risks from NAV erosion and dependency on AMD's stock performance pose significant challenges. Investors should weigh the income benefits against potential capital depreciation in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About YieldMax AMD Option Income Strategy ETF
AMDY is an active ETF that seeks to generate weekly income by selling call options on AMD stock. It aims to provide investors with high yield while maintaining exposure to the price movements of Advanced Micro Devices.
Read more on AMDY →
